An end to lawsuit is positive for Novo Nordisk, says analyst

Novo Nordisk gets out of a billion-dollar lawsuit in Denmark without paying plaintiffs or admitting wrongdoing. This is positive, says Analyst Søren Løntoft Hansen.
Photo: Dorthe Bach
Photo: Dorthe Bach
by marketwire, translated by daniel pedersen

On Friday, pharmaceutical firm Novo Nordisk settled a securities lawsuit in which shareholders had alleged Novo Nordisk had misled them about the insulin sales pressure on the US market and what this would mean for future sales.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading